Silo Pharma's QwikAgents Joins NVIDIA Developer Program

Silo Pharma, Inc. (NASDAQ:SILO) announced two significant developments in late June and early July. On July 7, the company reported that QwikAgents, its wholly owned subsidiary, had joined the NVIDIA Developer Program. This partnership grants QwikAgents access to NVIDIA's AI software ecosystem, development tools, technical resources, and optimization support. QwikAgents builds a platform designed to automate complex business processes through autonomous AI agents capable of reasoning, executing tasks, and connecting with enterprise systems. The company expects NVIDIA's resources to help accelerate platform development as it expands solutions for organizations seeking scalable AI-driven operations.

Separately, on June 29, Silo Pharma announced a partnership with Resyca to conduct a robustness evaluation of the microchip-based nasal spray technology underlying SPC-15, the company's lead intranasal treatment candidate for post-traumatic stress disorder. The study will assess device reliability during expected use and examine formulation stability over 30 days. Silo Pharma believes the nose-to-brain delivery approach may improve drug concentration in the brain while limiting systemic exposure, potentially supporting faster therapeutic effects and enhanced safety. The company is advancing SPC-15 development through regulatory discussions with the FDA, pursuing the streamlined 505 pathway.

Silo Pharma itself is a developmental-stage biopharmaceutical company combining psychedelic research with traditional therapeutics. Beyond SPC-15, the company is developing treatments for conditions including Alzheimer's disease, multiple sclerosis, and chronic pain.

Silo Pharma operates as a developmental-stage biopharmaceutical company that combines psychedelic research with traditional therapeutics. The company has two distinct business threads: its core psychedelic drug development work targeting conditions including PTSD, Alzheimer's disease, multiple sclerosis, and chronic pain, and its AI subsidiary QwikAgents, which builds autonomous agent technology for enterprise automation. The NVIDIA partnership announced on July 7 represents an effort to accelerate QwikAgents' technical capability by embedding it within NVIDIA's broader ecosystem. On the pharmaceutical side, the June 29 announcement of the Resyca partnership for evaluating its SPC-15 nasal spray formulation signals progress toward regulatory submission, with the company pursuing an FDA 505 pathway. The nose-to-brain delivery approach is intended to concentrate drug effects in the brain while reducing systemic side effects.